CN115364179B - Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN115364179B CN115364179B CN202211043216.7A CN202211043216A CN115364179B CN 115364179 B CN115364179 B CN 115364179B CN 202211043216 A CN202211043216 A CN 202211043216A CN 115364179 B CN115364179 B CN 115364179B
- Authority
- CN
- China
- Prior art keywords
- uric acid
- traditional chinese
- chinese medicine
- reducing blood
- blood uric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 58
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 229940116269 uric acid Drugs 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 39
- 210000004369 blood Anatomy 0.000 title claims abstract description 38
- 239000008280 blood Substances 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 26
- 241000132012 Atractylodes Species 0.000 claims abstract description 24
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 24
- 235000008113 selfheal Nutrition 0.000 claims abstract description 20
- 201000005569 Gout Diseases 0.000 claims abstract description 16
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 12
- 241000427159 Achyranthes Species 0.000 claims abstract description 10
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 9
- 235000011477 liquorice Nutrition 0.000 claims abstract description 9
- 239000002994 raw material Substances 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 84
- 239000000843 powder Substances 0.000 claims description 31
- 239000000284 extract Substances 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 25
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 14
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 claims description 12
- 239000007788 liquid Substances 0.000 claims description 12
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 claims description 12
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 239000001116 FEMA 4028 Substances 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 10
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 10
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 10
- 229960004853 betadex Drugs 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 9
- 239000000469 ethanolic extract Substances 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 9
- 210000000582 semen Anatomy 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- 239000011347 resin Substances 0.000 claims description 8
- 229920005989 resin Polymers 0.000 claims description 8
- 238000001694 spray drying Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 4
- 238000000889 atomisation Methods 0.000 claims description 2
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 20
- 201000001431 Hyperuricemia Diseases 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 229960003459 allopurinol Drugs 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 6
- 235000010674 Prunella vulgaris Nutrition 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 6
- 102100033220 Xanthine oxidase Human genes 0.000 description 6
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 238000010172 mouse model Methods 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 230000029142 excretion Effects 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000004144 purine metabolism Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- TYPSVDGIQAOBAD-DZGCQCFKSA-N Atractylone Chemical compound C([C@]1(C)C2)CCC(=C)[C@@H]1CC1=C2OC=C1C TYPSVDGIQAOBAD-DZGCQCFKSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 229960002708 antigout preparations Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- TYPSVDGIQAOBAD-UHFFFAOYSA-N atractylone Natural products C1C2(C)CCCC(=C)C2CC2=C1OC=C2C TYPSVDGIQAOBAD-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/536—Prunella or Brunella (selfheal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for reducing blood uric acid and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition for reducing blood uric acid comprises the following raw materials in parts by weight: 600-900 parts of selfheal, 10-50 parts of coptis chinensis, 10-50 parts of bighead atractylodes rhizome, 5-30 parts of coix seed, 5-30 parts of achyranthes root and 5-30 parts of liquorice. The invention takes the selfheal as the monarch drug, the coptis chinensis, the bighead atractylodes rhizome and the coix seed as the ministerial drugs, the achyranthes root as the conductant drug and the liquorice as the conductant drug, and the components are mutually matched, so that the invention effectively reduces the blood uric acid concentration and has wide application prospect in the aspects of preventing and treating gout.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for reducing blood uric acid as well as a preparation method and application thereof.
Background
Gout (gout) is a group of clinical syndromes caused by in vivo purine metabolic disorder or uric acid excretion reduction, resulting in deposition of uric acid at joints and the like in vivo, and continuous blood hyperuricemia is a necessary condition for initiating gout. Uric acid is a product of purine metabolism, and has limited solubility in body fluids, and when purine metabolism is disturbed or purine is taken up, excessive uric acid or uric acid excretion is reduced in the body, uric acid concentration accumulated in body fluids exceeds the saturation concentration, crystals are easily precipitated in tissues, hyperuricemia (hyperuricemia) is caused, and about 5-12% of patients suffering from hyperuricemia finally develop gout. Hyperuricemia is the most important biochemical basis of gout and is the most dangerous factor for inducing gout, so that uric acid level control is a key for preventing and reducing blood uric acid, and reducing blood uric acid concentration through medicines is an effective method for preventing gout.
The existing uric acid reducing medicines comprise two main medicines of uric acid excretion promoting medicines and uric acid synthesis inhibiting medicines, wherein the uric acid excretion promoting medicines are represented by benzbromarone, but are often accompanied by side effects such as rash, fever, kidney damage and the like; the drugs inhibiting uric acid synthesis act by acting on xanthine oxidase (xanthine oxidase), a key enzyme in uric acid production, and the most commonly used xanthine oxidase inhibitor in clinic is allopurinol (allopurinol); allopurinol has definite curative effect, however, about 2% of patients are allergic to allopurinol, about 3-10% of patients have adverse reactions in the treatment process, and toxic hepatitis can be induced, and adverse reactions such as gastrointestinal reactions, leucopenia and thrombocytopenia are accompanied. Therefore, research on high-efficiency anti-gout drugs has been urgent.
Disclosure of Invention
The invention discloses a traditional Chinese medicine composition for reducing blood uric acid and a preparation method and application thereof.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
a traditional Chinese medicine composition for reducing blood uric acid comprises the following raw materials in parts by weight:
600-900 parts of selfheal, 10-50 parts of coptis chinensis, 10-50 parts of bighead atractylodes rhizome, 5-30 parts of coix seed, 5-30 parts of achyranthes root and 5-30 parts of liquorice.
The traditional Chinese medicine composition of the invention uses the selfheal, and the active ingredient of the traditional Chinese medicine composition is rosmarinic acid. Modern researches show that after the human body ingests purine substances, uric acid is required to be generated under the action of xanthine oxidase, and rosmarinic acid has an inhibition effect on the xanthine oxidase, so that the generation of uric acid is inhibited. The Chinese pharmacopoeia prescribes that the rosmarinic acid content in the selfheal must not be lower than 0.2%, and researches show that the rosmarinic acid content in the selfheal in different producing places can reach 0.2% -2.3%. The invention takes the selfheal containing rosmarinic acid as the monarch drug in the prescription; is matched with coptis chinensis, bighead atractylodes rhizome and coix seed as ministerial drugs in the prescription; coptis chinensis is bitter and cold in nature, and has the effects of clearing heat and eliminating dampness; the bighead atractylodes rhizome has the effects of strengthening spleen and tonifying qi, and eliminating dampness and promoting diuresis, and is mainly used for treating spleen deficiency, anorexia and edema; semen coicis excreting dampness and strengthening spleen, relaxing tendons and removing arthralgia; the three medicines are combined together, so that the blood uric acid concentration can be effectively reduced by matching with the selfheal, and the pain of the joints of the channels and collaterals can be relieved. Achyranthes root, radix Achyranthis bidentatae, has the effects of promoting blood circulation, dredging channels, strengthening tendons and bones, and is an adjuvant drug in the recipe. So that it has the actions of regulating the actions of various medicines with licorice root and relieving pain. The traditional Chinese medicine has the effects of clearing heat, purging fire, promoting diuresis, removing dampness, strengthening tendons and bones and benefiting joints, and can be used for treating gout with symptoms of joint redness and swelling, heat pain, limited movement and the like caused by damp-heat accumulation.
The preparation method of the traditional Chinese medicine composition for reducing blood uric acid comprises the following steps:
(1) Reflux extracting Prunellae Spica with ethanol solution to obtain Prunellae Spica ethanol extractive solution;
(2) Recovering ethanol from Prunellae Spica ethanol extract, concentrating, and purifying with macroporous resin;
(3) Spray drying the purified extract to obtain rosmarinic acid-containing powder 1;
(4) Pulverizing part of Atractylodis rhizoma and Coicis semen to obtain powder 2;
(5) Decocting Coptidis rhizoma, achyranthis radix, glycyrrhrizae radix and the rest Atractylodis rhizoma and Coicis semen in water, filtering the decoction, concentrating the filtrate into paste, drying, and pulverizing to obtain powder 3;
(6) Powder 1, powder 2, and powder 3 were mixed.
The invention adopts the ethanol solution extraction and macroporous resin adsorption mode to extract and purify the traditional Chinese medicine selfheal rich in rosmarinic acid, can lead the content of rosmarinic acid in the extract to reach 10-20%, and can effectively inhibit xanthine oxidase activity and reduce blood uric acid concentration by matching with medicinal materials such as coptis chinensis, coix seeds, bighead atractylodes rhizome and the like, thereby achieving the effect of inhibiting gout occurrence and development.
In the invention, part of bighead atractylodes rhizome and coix seed are taken and directly crushed to be used as medicines, wherein the bighead atractylodes rhizome contains volatile components such as atractylone and the like, and the crushing to be used as medicines ensures that part of volatile active components are reserved; the coix seed medicinal material has stronger powder property, and the addition of auxiliary materials in the preparation can be reduced by crushing and taking the coix seed medicinal material into the medicine.
The medicines such as coptis chinensis, achyranthes root and liquorice are extracted by adopting a water decoction method, and most of the active ingredients of the medicines have better solubility in water, so that the full extraction of the active ingredients can be ensured.
Preferably, in the step (1), the ethanol solution with the mass fraction of 40-95% is used for reflux extraction for 1-3 times, each time for 0.5-2.5 hours, and the use amount of the ethanol solution for each reflux extraction is 4-10 times of the weight of the selfheal.
Preferably, in the step (2), the ethanol extract of the selfheal is recovered until no ethanol smell exists, and the ethanol extract is concentrated; passing through D101 macroporous resin, washing with water, discarding water washing liquid, eluting with 20-80% ethanol solution, collecting ethanol eluate, and recovering ethanol to obtain purified extract.
Preferably, the water and the 20-80% ethanol solution by mass fraction are used in an amount of 4 times the column volume.
Preferably, in the step (3), the purified extract is added with starch and beta cyclodextrin, and is spray dried, wherein the air inlet temperature of the drying is 150-160 ℃, the air outlet temperature is 80-90 ℃, the inlet volume flow is 15mL/min, and the atomization air flow pressure is 220Pa.
Preferably, the starch is used in an amount of 10% by mass of the purified extract and the beta cyclodextrin is used in an amount of 10-15% by mass of the purified extract.
Preferably, in the step (4), the dosage of the bighead atractylodes rhizome and the coix seed is one third of the dosage of the prescription; pulverizing, and sieving with 80 mesh sieve.
Preferably, in the step (5), water is added for 2 times, each time is 1.5 hours, and the water addition amount is 6-8 times of the weight of the medicinal materials; mixing decoctions, filtering, concentrating the filtrate into soft extract with relative density of 1.25-1.30 at 80deg.C, controlling vacuum degree to less than or equal to 0.08MPa, drying under reduced pressure at 70-80deg.C to obtain dry extract, pulverizing, and sieving with 80 mesh sieve.
The traditional Chinese medicine composition or the traditional Chinese medicine composition prepared by the method is applied to the preparation of medicines for reducing blood uric acid and preventing or treating gout.
In conclusion, the invention takes the selfheal as the monarch drug, the coptis chinensis, the bighead atractylodes rhizome and the coix seed as the ministerial drugs, the achyranthes root as the adjuvant drug and the liquorice as the guiding drug, and the medicines are matched with each other, so that the blood uric acid concentration is effectively reduced, and the invention has wide application prospect in the aspects of preventing and treating gout.
Detailed Description
The following description of the embodiments of the present invention will be made clearly and completely, and it is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention.
Example 1
A Chinese medicinal composition for reducing blood uric acid comprises the following raw materials:
750g of selfheal, 30g of coptis chinensis, 30g of bighead atractylodes rhizome, 15g of coix seed, 15g of achyranthes root and 15g of liquorice.
The preparation method of the traditional Chinese medicine composition for reducing blood uric acid comprises the following steps:
(1) Reflux-extracting Prunella vulgaris with 70% ethanol solution for 2 times (each for 1 hr) with an amount of 6 times of the weight of Prunella vulgaris; filtering after extraction, and combining the filtrates to obtain the selfheal ethanol extract.
(2) Recovering ethanol from Prunellae Spica ethanol extractive solution until no ethanol smell is present, and concentrating to obtain medicinal liquid with a mass ratio of 1:1; passing through D101 macroporous resin, washing with 4 times of column volume, discarding the water washing liquid, eluting with 50% ethanol solution with 4 times of column volume mass fraction, collecting ethanol eluate, and recovering ethanol to obtain purified extract.
(3) Adding starch and beta cyclodextrin into the purified extract, and spray drying to obtain rosmarinic acid-containing powder 1;
the temperature of the drying inlet air is controlled at 150-160 ℃, the temperature of the exhaust air is controlled at 80-90 ℃, the volume flow rate of the inlet liquid is 15mL/min, and the pressure of the atomized air flow is 220Pa. The starch amount was 10% of the purified extract mass and the beta cyclodextrin amount was 10% of the purified extract mass.
(4) Taking one third of the weight of the prescription, namely, largehead atractylodes rhizome and coix seed, crushing the largehead atractylodes rhizome and the coix seed, and sieving the crushed largehead atractylodes rhizome and coix seed with a 80-mesh sieve to obtain powder 2.
(5) Decocting Coptidis rhizoma, achyranthis radix, glycyrrhrizae radix and the rest Atractylodis rhizoma and Coicis semen in water for 2 times (1.5 hr each time) with water amount of 8-6 times of the weight of the medicinal materials respectively; mixing decoctions, filtering, concentrating the filtrate to relative density of 1.25-1.30 (measured at 80deg.C), vacuum drying at 70-80deg.C under vacuum degree of less than or equal to 0.08MPa to obtain dry extract, pulverizing, and sieving with 80 mesh sieve to obtain powder 3.
(6) Powder 1, powder 2, and powder 3 were mixed.
The Chinese medicinal composition can be made into pill, capsule or tablet for reducing blood uric acid, and preventing and treating gout.
Example 2
A Chinese medicinal composition for reducing blood uric acid comprises the following raw materials:
800g of selfheal, 20g of coptis chinensis, 40g of bighead atractylodes rhizome, 10g of coix seed, 10g of achyranthes root and 25g of liquorice.
The preparation method of the traditional Chinese medicine composition for reducing blood uric acid comprises the following steps:
(1) Reflux-extracting Prunella vulgaris with 75% ethanol solution for 3 times (each time for 0.5 hr) with an amount of 4 times of the weight of Prunella vulgaris; filtering after extraction, and combining the filtrates to obtain the selfheal ethanol extract.
(2) Recovering ethanol from Prunellae Spica ethanol extractive solution until no ethanol smell is present, and concentrating to obtain medicinal liquid with a mass ratio of 1:1; passing through D101 macroporous resin, washing with 4 times of column volume, discarding the water washing liquid, eluting with 70% ethanol solution with 4 times of column volume mass fraction, collecting ethanol eluate, and recovering ethanol to obtain purified extract.
(3) Adding starch and beta cyclodextrin into the purified extract, and spray drying to obtain rosmarinic acid-containing powder 1;
the temperature of the drying inlet air is controlled at 150-160 ℃, the temperature of the exhaust air is controlled at 80-90 ℃, the volume flow rate of the inlet liquid is 15mL/min, and the pressure of the atomized air flow is 220Pa. Starch is used in an amount of 10% by mass of the purified extract and beta cyclodextrin is used in an amount of 15% by mass of the purified extract.
(4) Taking one third of the weight of the prescription, namely, largehead atractylodes rhizome and coix seed, crushing the largehead atractylodes rhizome and the coix seed, and sieving the crushed largehead atractylodes rhizome and coix seed with a 80-mesh sieve to obtain powder 2.
(5) Decocting Coptidis rhizoma, achyranthis radix, glycyrrhrizae radix and the rest Atractylodis rhizoma and Coicis semen in water for 2 times (1.5 hr each time) with water amount of 8-6 times of the weight of the medicinal materials respectively; mixing decoctions, filtering, concentrating the filtrate to relative density of 1.25-1.30 (measured at 80deg.C), vacuum drying at 70-80deg.C under vacuum degree of less than or equal to 0.08MPa to obtain dry extract, pulverizing, and sieving with 80 mesh sieve to obtain powder 3.
(6) Powder 1, powder 2, and powder 3 were mixed.
The Chinese medicinal composition can be made into pill, capsule or tablet for reducing blood uric acid, and preventing and treating gout.
Example 3
A Chinese medicinal composition for reducing blood uric acid comprises the following raw materials:
700g of selfheal, 40g of coptis chinensis, 20g of bighead atractylodes rhizome, 20g of coix seed, 20g of achyranthes root and 20g of liquorice.
The preparation method of the traditional Chinese medicine composition for reducing blood uric acid comprises the following steps:
(1) Reflux-extracting Prunella vulgaris with 80% ethanol solution for 2 times (each for 2 hr) with an amount of 8 times of the weight of Prunella vulgaris; filtering after extraction, and combining the filtrates to obtain the selfheal ethanol extract.
(2) Recovering ethanol from Prunellae Spica ethanol extractive solution until no ethanol smell is present, and concentrating to obtain medicinal liquid with a mass ratio of 1:1; passing through D101 macroporous resin, washing with 4 times of column volume, discarding the water washing liquid, eluting with 60% ethanol solution with 4 times of column volume mass fraction, collecting ethanol eluate, and recovering ethanol to obtain purified extract.
(3) Adding starch and beta cyclodextrin into the purified extract, and spray drying to obtain rosmarinic acid-containing powder 1;
the temperature of the drying inlet air is controlled at 150-160 ℃, the temperature of the exhaust air is controlled at 80-90 ℃, the volume flow rate of the inlet liquid is 15mL/min, and the pressure of the atomized air flow is 220Pa. The starch amount was 10% of the purified extract mass and the beta cyclodextrin amount was 10% of the purified extract mass.
(4) Taking one third of the weight of the prescription, namely, largehead atractylodes rhizome and coix seed, crushing the largehead atractylodes rhizome and the coix seed, and sieving the crushed largehead atractylodes rhizome and coix seed with a 80-mesh sieve to obtain powder 2.
(5) Decocting Coptidis rhizoma, achyranthis radix, glycyrrhrizae radix and the rest Atractylodis rhizoma and Coicis semen in water for 2 times (1.5 hr each time) with water amount of 8-6 times of the weight of the medicinal materials respectively; mixing decoctions, filtering, concentrating the filtrate to relative density of 1.25-1.30 (measured at 80deg.C), vacuum drying at 70-80deg.C under vacuum degree of less than or equal to 0.08MPa to obtain dry extract, pulverizing, and sieving with 80 mesh sieve to obtain powder 3.
(6) Powder 1, powder 2, and powder 3 were mixed.
The Chinese medicinal composition can be made into pill, capsule or tablet for reducing blood uric acid, and preventing and treating gout.
Example 4
Experimental animals: kunming mice, SPF grade, male, supplied by Liaoning Changsheng Biotechnology Co., ltd., laboratory animal production license number: SCXK (Liao) 2020-0001.
Experimental animal use license number: SYXK 2022-0004. The feeding environment is a shielding environment, and free ingestion and drinking water are realized; the feed is provided by the company of the company australia of the beijing family, production license number: SCXK (jin) 2020-0004, lot number: 22013211.
male Kunming mice weighing 20-22 g are randomly divided into 7 groups, namely a normal control group, a model control group, and 5mg/kg group of allopurinol (supplied by Hefei Jiujia pharmaceutical Co., ltd., batch number: 20180502), 4g/kg group of four wonderful pills (rhizoma Atractylodis, radix Achyranthis bidentatae, cortex Phellodendri and semen Coicis), 4g/kg group of the traditional Chinese medicine composition of example 1, 2g/kg group of the traditional Chinese medicine composition of example 1 and 1g/kg group of the traditional Chinese medicine composition of example 1, and 10 groups each.
Each group is respectively subjected to gastric lavage administration at a ratio of 8:00 (am), each administration group is subjected to gastric lavage by using a solution prepared by 0.25% sodium carboxymethylcellulose (CMC) water solution, and the gastric lavage volume is 20mL/kg for 6 days; the normal control and model control were gavaged with equal amounts of 0.25% cmc solution.
After 1 hour of daily administration, 250mg/kg of potassium oxazinate (supplied by Dalian Mei Lun Biotechnology Co., ltd., batch No. A0925A, prepared into the desired concentration with distilled water before use, adjusted to pH7.5 with 1NKOH solution) was administered intraperitoneally to the model control group and each of the administration groups, respectively, and an equivalent amount of physiological saline was administered intraperitoneally to the normal control group. Blood is collected from the retrobulbar venous plexus of the mice 1h after the last administration of the potassium oxazinate, and the mice are centrifuged at 3000rpm/min for 10min, serum is collected, and serum uric acid level is measured by a phosphotungstic acid reduction method according to a uric acid measuring kit (provided by Nanjing institute of biological engineering, lot number: 20212225) instruction book.
Statistical analysis data were analyzed in + -s, and comparisons between groups used one-way analysis of variance.
The experimental results are shown in Table 1. The blood uric acid levels of the animals of the model control group were compared with the normal control group, and the difference had statistical significance (P < 0.01), indicating that the model was successful. The positive drug allopurinol 5mg/kg has extremely obvious inhibiting effect (P < 0.001) on the serum uric acid level of a hyperuricemia mouse model, the four wonderful pill 4g/kg group has obvious inhibiting effect (P < 0.05) on the serum uric acid level of the hyperuricemia mouse model, and the composition 4g/kg group and the composition 2g/kg group of the example 1 have obvious inhibiting effect (P < 0.01) on the serum uric acid level of the hyperuricemia mouse model. 1g/kg has obvious inhibiting effect (P < 0.05) on serum uric acid level of hyperuricemia mice model.
TABLE 1
Comparison with the normal control group: : # # p <0.001 compared to model control: * p <0.05, < p <0.01, < p <0.001.
The study adopts a potassium oxazinate-induced mouse hyperuricemia model, and uses allopurinol as a positive control to study the influence of the administration of the traditional Chinese medicine composition of the embodiment 1 with different administration concentrations on serum uric acid level of the hyperuricemia mouse model. The results show that the traditional Chinese medicine composition 4g/kg and 2g/kg in the example 1 have certain effect of reducing blood uric acid, the effect is obviously stronger than that of a four-wonderful pill group, and xanthine oxidase is inhibited as one of the action targets.
In the present specification, each embodiment is described in a progressive manner, and each embodiment is mainly described in a different point from other embodiments, and identical and similar parts between the embodiments are all enough to refer to each other.
The previous description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the present invention. Various modifications to the embodiments described above will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein.
Claims (10)
1. The traditional Chinese medicine composition for reducing blood uric acid is characterized by comprising the following raw materials in parts by weight:
800 parts of selfheal, 20 parts of coptis chinensis, 40 parts of bighead atractylodes rhizome, 10 parts of coix seed, 10 parts of achyranthes root and 25 parts of liquorice.
2. The method for preparing the traditional Chinese medicine composition for reducing blood uric acid as defined in claim 1, which is characterized by comprising the following steps:
(1) Reflux extracting Prunellae Spica with ethanol solution to obtain Prunellae Spica ethanol extractive solution;
(2) Recovering ethanol from Prunellae Spica ethanol extract, concentrating, and purifying with macroporous resin;
(3) Spray drying the purified extract to obtain rosmarinic acid-containing powder 1;
(4) Pulverizing part of Atractylodis rhizoma and Coicis semen to obtain powder 2;
(5) Decocting Coptidis rhizoma, achyranthis radix, glycyrrhrizae radix and the rest Atractylodis rhizoma and Coicis semen in water, filtering the decoction, concentrating the filtrate into paste, drying, and pulverizing to obtain powder 3;
(6) Powder 1, powder 2, and powder 3 were mixed.
3. The method for preparing the traditional Chinese medicine composition for reducing blood uric acid according to claim 2, which is characterized in that,
in the step (1), reflux-extracting with 40-95% ethanol solution for 1-3 times, each time for 0.5-2.5 hr, wherein the amount of ethanol solution in each reflux-extraction is 4-10 times of the weight of Prunellae Spica.
4. The method for preparing the traditional Chinese medicine composition for reducing blood uric acid according to claim 2, which is characterized in that,
in the step (2), the ethanol extract of the selfheal is recovered until no ethanol smell exists, and the ethanol extract is concentrated; passing through D101 macroporous resin, washing with water, discarding water washing liquid, eluting with 20-80% ethanol solution, collecting ethanol eluate, and recovering ethanol to obtain purified extract.
5. The method for preparing a Chinese medicinal composition for reducing blood uric acid according to claim 4, wherein,
the dosage of water and the ethanol solution with the mass fraction of 20-80% is 4 times of the volume of the column.
6. The method for preparing the traditional Chinese medicine composition for reducing blood uric acid according to claim 2, which is characterized in that,
in the step (3), starch and beta cyclodextrin are added into the purified extract, the spray drying is carried out, the drying inlet air temperature is 150-160 ℃, the exhaust air temperature is 80-90 ℃, the inlet liquid volume flow is 15mL/min, and the atomization air flow pressure is 220Pa.
7. The method for preparing a Chinese medicinal composition for reducing blood uric acid as defined in claim 6, wherein,
the starch is used in an amount of 10% by mass of the purified extract, and the beta cyclodextrin is used in an amount of 10-15% by mass of the purified extract.
8. The method for preparing the traditional Chinese medicine composition for reducing blood uric acid according to claim 2, which is characterized in that,
in the step (4), the dosage of the bighead atractylodes rhizome and the coix seed is one third of the dosage of the prescription; pulverizing, and sieving with 80 mesh sieve.
9. The method for preparing the traditional Chinese medicine composition for reducing blood uric acid according to claim 2, which is characterized in that,
in the step (5), water is added for 2 times, each time lasts for 1.5 hours, and the water adding amount is 6-8 times of the weight of the medicinal materials; mixing decoctions, filtering, concentrating the filtrate into soft extract with relative density of 1.25-1.30 at 80deg.C, controlling vacuum degree to less than or equal to 0.08MPa, drying under reduced pressure at 70-80deg.C to obtain dry extract, pulverizing, and sieving with 80 mesh sieve.
10. The use of the traditional Chinese medicine composition of claim 1 or the traditional Chinese medicine composition prepared by the method of any one of claims 2-9 in the preparation of medicines for reducing blood uric acid and preventing or treating gout.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211043216.7A CN115364179B (en) | 2022-08-29 | 2022-08-29 | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211043216.7A CN115364179B (en) | 2022-08-29 | 2022-08-29 | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115364179A CN115364179A (en) | 2022-11-22 |
| CN115364179B true CN115364179B (en) | 2024-02-06 |
Family
ID=84068792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211043216.7A Active CN115364179B (en) | 2022-08-29 | 2022-08-29 | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115364179B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101596295A (en) * | 2009-07-03 | 2009-12-09 | 云南天秀植物科技开发有限公司 | A kind of pharmaceutical composition and preparation technology thereof who is used for the treatment of gout |
| CN102018759A (en) * | 2009-09-17 | 2011-04-20 | 上海中医药大学附属曙光医院 | Rosmarinic acid, rosmarinic acid-containing common selfheal fruit-spike active ingredient and preparation methods and application thereof to prevention and treatment of cancer postoperative metastasis |
| CN102671076A (en) * | 2012-05-14 | 2012-09-19 | 吴敏 | Medicament for treating gout |
| CN104997843A (en) * | 2015-08-07 | 2015-10-28 | 国药集团健康产业研究院有限公司 | Application of selfheal extract for making blood uric acid decreasing medicine or food |
| CN105055510A (en) * | 2015-09-14 | 2015-11-18 | 青岛大学 | Effective part of perilla leaf resisting hyperuricemia and preparation method and application thereof |
-
2022
- 2022-08-29 CN CN202211043216.7A patent/CN115364179B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101596295A (en) * | 2009-07-03 | 2009-12-09 | 云南天秀植物科技开发有限公司 | A kind of pharmaceutical composition and preparation technology thereof who is used for the treatment of gout |
| CN102018759A (en) * | 2009-09-17 | 2011-04-20 | 上海中医药大学附属曙光医院 | Rosmarinic acid, rosmarinic acid-containing common selfheal fruit-spike active ingredient and preparation methods and application thereof to prevention and treatment of cancer postoperative metastasis |
| CN102671076A (en) * | 2012-05-14 | 2012-09-19 | 吴敏 | Medicament for treating gout |
| CN104997843A (en) * | 2015-08-07 | 2015-10-28 | 国药集团健康产业研究院有限公司 | Application of selfheal extract for making blood uric acid decreasing medicine or food |
| CN105055510A (en) * | 2015-09-14 | 2015-11-18 | 青岛大学 | Effective part of perilla leaf resisting hyperuricemia and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 加味四妙胶囊抗痛风性关节炎实验研究;苗艳波 等;北华大学学报(自然科学版);第18卷(第05期);606-608 * |
| 自拟排石汤加减治疗原发性痛风50例;陈桂德;广西中医药;-(第04期);第19页"治疗方法"、"讨论与体会" * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115364179A (en) | 2022-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101632827B (en) | Traditional Chinese medicine composition for treating psoriasis and preparation method thereof | |
| CN112716989B (en) | Celery seed extract and preparation method and application thereof | |
| CN100427063C (en) | An wind-expelling ointment and method for preparing same | |
| KR101088539B1 (en) | Chinese medicinal compositions for treating headache, formulations and processes for preparation therof | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN105727144A (en) | Traditional Chinese medicine composition for treating bronchitis and preparation method thereof | |
| CN102626468B (en) | Traditional Chinese medicine combination for treating hepatitis B and preparing method and application thereof | |
| CN112494616B (en) | Traditional Chinese medicine composition for inhibiting early development and sexual precocity of children and preparation method and application thereof | |
| CN115364179B (en) | Traditional Chinese medicine composition for reducing blood uric acid as well as preparation method and application thereof | |
| CN103083433A (en) | Drug for treating rheumatism and rheumatoid sciatica | |
| CN1709326A (en) | Method for preparing concentrated pill for treating mammary gland proliferation disease | |
| CN103394002B (en) | Medicinal composition for treating cutaneous pruritus as well as preparation method and application thereof | |
| CN115554325A (en) | Application of medicine terminalia fruit, extractive or preparation thereof in preparing anti-inflammatory, analgesic or uric acid-reducing medicines | |
| CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
| CN102940747B (en) | Medicine composition for treating gout | |
| CN112826917A (en) | Compound mulberry and astragalus traditional Chinese medicine composition and application thereof | |
| CN1319546C (en) | Delayed-releasing preparation for treating osteoporosis | |
| CN106266002B (en) | Traditional Chinese medicine composition for treating hyperuricemia | |
| CN106377651A (en) | Preparation method for extracting pharmaceutical monomer for preventing and treating hyperuricemia and gout from rhizoma smilacis glabrae | |
| CN112168931B (en) | A pharmaceutical composition for treating oral ulcer, and its preparation method | |
| CN1158093C (en) | Medicine composition containing yak bone for treating rhenmatism and method for making same | |
| CN101433707A (en) | Method for preparing coptis root soup formulation | |
| CN101757460A (en) | Traditional Chinese medicine preparation for treating gout | |
| CN107693618B (en) | Pharmaceutical composition for treating kidney deficiency and preparation method and application thereof | |
| CN1569085A (en) | Pharmaceutical composition for treating rheumatic arthritis and rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |